Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Wallentin

Showing results (161-170 of 186) with videos related to

Pageof 19
Sort By:
Clinical Cardiology|April 5, 2001
Evaluating the place of low-molecular-weight heparin in the management of acute coronary syndromes. A panel discussion with audience participationJ H Chesebro, F W Verheugt, F Kontny, et al.
Heart (British Cardiac Society)|September 18, 2014
Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapyM Janzon, S James, C P Cannon, et al.
Heart (British Cardiac Society)|October 13, 2007
Risk stratification in ST-elevation myocardial infarction is enhanced by combining baseline ST deviation and subsequent ST-segment resolutionM Toma, Y Fu, G Wagner, et al.
European Heart Journal|September 21, 2002
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromesS James, P Armstrong, R Califf, et al.
Heart (British Cardiac Society)|July 16, 2005
FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery diseaseB Lagerqvist, E Diderholm, B Lindahl, et al.
Journal of the American College of Cardiology|March 18, 1999
Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II)G Frostfeldt, G Ahlberg, G Gustafsson, et al.
Lakartidningen|December 22, 1999
[Use of percutaneous coronary vessel interventions should be increased. 400 interventions per year is a minimum capacity of decentralized services]L Wallentin, T Nilsson, L Bergfeldt, et al.
European Heart Journal|July 20, 2002
A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS)D Hasdai, S Behar, L Wallentin, et al.
Journal of Internal Medicine|May 10, 2021
Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndromeM Olszowka, C Held, N Hadziosmanovic, et al.
European Heart Journal|September 3, 2004
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACSJ P Ottervanger, P Armstrong, E S Barnathan, et al.
Pageof 19

Showing results (161-170 of 186) with videos related to

Sort By:
Pageof 19
Clinical Cardiology|April 5, 2001
Evaluating the place of low-molecular-weight heparin in the management of acute coronary syndromes. A panel discussion with audience participationJ H Chesebro, F W Verheugt, F Kontny, et al.
Heart (British Cardiac Society)|September 18, 2014
Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapyM Janzon, S James, C P Cannon, et al.
Heart (British Cardiac Society)|October 13, 2007
Risk stratification in ST-elevation myocardial infarction is enhanced by combining baseline ST deviation and subsequent ST-segment resolutionM Toma, Y Fu, G Wagner, et al.
European Heart Journal|September 21, 2002
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromesS James, P Armstrong, R Califf, et al.
Heart (British Cardiac Society)|July 16, 2005
FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery diseaseB Lagerqvist, E Diderholm, B Lindahl, et al.
Journal of the American College of Cardiology|March 18, 1999
Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II)G Frostfeldt, G Ahlberg, G Gustafsson, et al.
Lakartidningen|December 22, 1999
[Use of percutaneous coronary vessel interventions should be increased. 400 interventions per year is a minimum capacity of decentralized services]L Wallentin, T Nilsson, L Bergfeldt, et al.
European Heart Journal|July 20, 2002
A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS)D Hasdai, S Behar, L Wallentin, et al.
Journal of Internal Medicine|May 10, 2021
Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndromeM Olszowka, C Held, N Hadziosmanovic, et al.
European Heart Journal|September 3, 2004
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACSJ P Ottervanger, P Armstrong, E S Barnathan, et al.
Pageof 19